Malignancy and cancer therapies are associated with clinical thrombosis, representing a significant complication that requires specialized approaches to diagnosis and treatment.
This review summarizes the epidemiology, pathogenesis, diagnosis, and treatment of thromboembolic complications in cancer patients.
Absolute Event Rate: 0% vs 0%
The association between malignancy and clinical thrombosis has been recognized for nearly 140 years. The purpose of this review is to examine our current understanding of thrombosis as a complication of cancer and cancer therapy. The review includes a discussion of the epidemiology, pathophysiology, diagnosis and treatment.
Sutherland et al. (Mon,) reported a other. Malignancy and cancer therapies are associated with clinical thrombosis, representing a significant complication that requires specialized approaches to diagnosis and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: